Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 203-453-4 | CAS number: 107-02-8
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Administrative data
Description of key information
The available data do not indicate that the central nervous system or peripheral nervous system are targets of acrolein toxicity.
Key value for chemical safety assessment
Additional information
Acrolein has been the subject of a risk assessment carried out under Community Regulation (EEC) No 793/93 (EU, 2001). However, neurotoxicity is no specific chapter in the EU Risk Assessment. The key information on neurotoxicity as stated correspond to the greatest extend to further assessments carried out under other international and national programmes published after finalisation of the EU Risk Assessment Report 2001 (World Health Organization, International Programme on Chemical Safety (IPCS), Concise International Chemical Assessment Document of Acrolein, CICADS 43 (WHO, 2002) and United States Agency for Toxic Substances and Desease Registry, Toxicological Profile for Acrolein (US ATSDR, 2007)):
1. European Union Risk Assessment Report of Acrolein (EU, 2001)
There is no specific chapter on neurotoxicity in the EU Risk assessment.
2. Agreement with further International Reports and Studies Published after Finalisation of the EU Risk Assessment Report 2001
Not applicable.
3. Substantial Disagreements in Comparison to further International Reports to European Union Risk Assessment Report 2001
Not applicable.
4. Additional Aspects in further International Reports
US ATSDR, 2007: No information was located regarding neurological effects of acrolein in humans. Symptoms of central nervous system depression were observed in rodents after oral exposure to acrolein, but only after lethal concentrations (Sprince et al. 1979). No such effects were observed in animals after inhalation exposure; the animals died from asphyxia caused by epithelial desquamation and, consequently, respiratory obstruction (Ballantyne et al. 1989; Catilina et al. 1966; Crane et al. 1986; Skog 1950). No behavioral changes were observed in animals exposed to acrolein by any route. Nonspecific histopathological effects on the brains (remark: nonspecific inflammatory responses in sections of the brain of animals were found in subchronic inhalation studies (Feron et al. 1978; Kutzman et al. 1984, 1985; Lyon et al. 1970). No histopathological changes in neurological tissues were observed after oral exposure (Parent et al. 1991a, 1992a, 1992b). No studies regarding neurotoxicity of acrolein after dermal exposure were located. However, the available data do not indicate that the central nervous system is the major target of acrolein toxicity.” quotation from US ATSDR, 2007, 89-90 (information of remark from p40), identical information as quotation from US ATSDR in United States Environmental Protection Agency, HED Risk Assessment for Reregistration Eligibility Decision (RED) Document for Acrolein (US-EPA, 2008).
WHO 2002: “Limited data on neurotoxicity indicate a lack of morphological changes in the tracheal or pulmonary nerves of rats exposed by inhalation to up to 570 mg acrolein/m³ (249 ppm) for 10 min (Springall et al., 1990), no histopathological changes in the nerve cells of the nasal olfactory epithelium of mice exposed by inhalation to 3.9 mg acrolein/m³ (1.7 ppm) for 6 h/day for 5 days (Buckley et al., 1984), and no behavioural effects in rats exposed by inhalation to up to 9.2 mg acrolein/m³ (4.0 ppm) for 6 h/ day, 5 days/week, for up to 62 days (Kutzman et al., 1984).” Quotation from WHO, 2002, p27
5. Additional Information in Newer Studies, not Included in the European Union Risk Assessment Report 2001 or further Cited International Reports
None
Justification for classification or non-classification
The available data do not indicate that the central nervous system or peripheral nervous system are targets of acrolein toxicity.
Thus, acrolein does not comply with the classification requirements regarding neurotoxicity outlined in regulation (EC) 1272/2008 or the former directive on classification and labelling 67/548/EWG.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
